Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
NOTV
Upturn stock ratingUpturn stock rating

Inotiv Inc (NOTV)

Upturn stock ratingUpturn stock rating
$4.05
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/24/2025: NOTV (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

3 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $5.5

1 Year Target Price $5.5

Analysts Price Target For last 52 week
$5.5Target price
Low$1.15
Current$4.05
high$6.48

Analysis of Past Performance

Type Stock
Historic Profit -7.91%
Avg. Invested days 24
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/24/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 58.40M USD
Price to earnings Ratio -
1Y Target Price 5.5
Price to earnings Ratio -
1Y Target Price 5.5
Volume (30-day avg) 3
Beta 4.1
52 Weeks Range 1.15 - 6.48
Updated Date 06/30/2025
52 Weeks Range 1.15 - 6.48
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -3.12

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -18.21%
Operating Margin (TTM) -7.62%

Management Effectiveness

Return on Assets (TTM) -2.31%
Return on Equity (TTM) -47.95%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 490695062
Price to Sales(TTM) 0.12
Enterprise Value 490695062
Price to Sales(TTM) 0.12
Enterprise Value to Revenue 1.02
Enterprise Value to EBITDA 86.8
Shares Outstanding 34353000
Shares Floating 31206932
Shares Outstanding 34353000
Shares Floating 31206932
Percent Insiders 11.32
Percent Institutions 23.8

Analyst Ratings

Rating 2
Target Price 5.5
Buy -
Strong Buy 2
Buy -
Strong Buy 2
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Inotiv Inc

stock logo

Company Overview

overview logo History and Background

Inotiv, Inc. was founded in 1974 as Bioanalytical Systems, Inc. (BASi). It has grown through acquisitions and organic expansion, transforming from a provider of bioanalytical services to a broader contract research organization (CRO) serving the drug discovery and development market. Significant milestones include strategic acquisitions of companies specializing in toxicology, pharmacology, and related services.

business area logo Core Business Areas

  • Discovery and Safety Assessment: Provides comprehensive preclinical services, including toxicology, pathology, pharmacology, and bioanalysis, to help pharmaceutical, biotechnology, and government entities discover and develop new drugs and therapies. This includes conducting safety and efficacy studies.
  • Research Models and Services: Offers a variety of research models, including genetically modified animals and related services, supporting preclinical research and development. This includes the sourcing, breeding, and characterization of research models.
  • Analytical Services: Provides services, including bioanalysis, drug metabolism and pharmacokinetics (DMPK), and formulation development, which supports drug development and regulatory compliance.

leadership logo Leadership and Structure

The leadership team consists of the CEO, CFO, COO, and various VPs responsible for different business units. The organizational structure is hierarchical, with reporting lines from business unit leaders to executive management. The company is governed by a Board of Directors.

Top Products and Market Share

overview logo Key Offerings

  • Toxicology Services: Offers a range of toxicology studies to assess the safety of drug candidates. The market is highly competitive with companies like Charles River Laboratories (CRL), WuXi AppTec (WX), and Labcorp (LH). Market share data is not publicly disclosable but estimated to be low single digits given the fragmented market.
  • Research Models: Provides various research models, including genetically modified animals, for preclinical research. Competitors include Charles River Laboratories (CRL), Envigo (private), and Taconic Biosciences (private). Market share is in the low single digits.
  • Bioanalytical Services: Offers a range of analytical testing services to assess the safety of drug candidates. The market is highly competitive with companies like Charles River Laboratories (CRL), WuXi AppTec (WX), and Labcorp (LH). Market share data is not publicly disclosable but estimated to be low single digits given the fragmented market.

Market Dynamics

industry overview logo Industry Overview

The contract research organization (CRO) industry is experiencing growth driven by increasing R&D spending in the pharmaceutical and biotechnology sectors, rising demand for outsourcing, and increasing complexity of drug development. This includes services from discovery to phase IV clinical trials and post-market support.

Positioning

Inotiv is positioned as a mid-sized CRO specializing in preclinical research and development services. Its competitive advantage lies in its integrated service offerings and expertise in specialized areas such as toxicology and research models.

Total Addressable Market (TAM)

The total addressable market for preclinical CRO services is estimated to be in the billions of dollars. Inotiv is positioned to capture a portion of this market through its specialized service offerings.

Upturn SWOT Analysis

Strengths

  • Comprehensive preclinical service offerings
  • Expertise in toxicology and pharmacology
  • Established relationships with pharmaceutical and biotechnology clients
  • Strategic acquisitions to expand capabilities
  • Offers diverse Research Models

Weaknesses

  • High debt level
  • Relatively small scale compared to larger CROs
  • Integration challenges from acquisitions
  • Dependence on key clients and contracts
  • Low profit margins

Opportunities

  • Growing demand for preclinical CRO services
  • Expansion into new geographic markets
  • Increased outsourcing by pharmaceutical companies
  • Development of new service offerings
  • Market Consolidation by Acquisition

Threats

  • Intense competition from larger CROs
  • Economic downturn impacting R&D spending
  • Regulatory changes in drug development
  • Loss of key personnel
  • Supply chain disruptions

Competitors and Market Share

competitor logo Key Competitors

  • CRL
  • LH
  • WX

Competitive Landscape

Inotiv Inc faces intense competition from larger CROs such as Charles River Laboratories, Labcorp, and WuXi AppTec. Its advantages include specialized service offerings and established relationships with clients. Its disadvantages include smaller scale, high debt, and integration challenges.

Major Acquisitions

Envigo RMS Holding Corp

  • Year: 2021
  • Acquisition Price (USD millions): 545.5
  • Strategic Rationale: Expanded research models and services capabilities and market presence.

Bolder BioPATH, Inc

  • Year: 2023
  • Acquisition Price (USD millions): 11.2
  • Strategic Rationale: Expanded research models and services capabilities and market presence.

Growth Trajectory and Initiatives

Historical Growth: Inotiv Inc.'s historical growth has been driven by acquisitions and organic expansion. Revenue growth has been inconsistent, with periods of rapid growth followed by periods of slower growth or decline.

Future Projections: Future growth projections are based on analyst estimates, which vary depending on market conditions and the company's ability to execute its strategic plan. The company is expected to benefit from increased R&D spending and outsourcing trends.

Recent Initiatives: Recent strategic initiatives include acquisitions of companies specializing in toxicology and pharmacology, expansion of service offerings, and investments in new technologies. The company has also focused on integrating its acquired businesses and improving operational efficiency.

Summary

Inotiv, Inc. is a mid-sized CRO with specialized preclinical service offerings that is struggling to compete with larger players. It has grown through acquisition, expanding capabilities in toxicology, research models, and analytical services. The company faces challenges managing debt, integrating acquired businesses, and maintaining profitability. Inotiv needs to focus on improving operational efficiency and organic growth to improve their standing in the market.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings
  • Analyst reports
  • Industry publications

Disclaimers:

This analysis is based on available information and is subject to change. It is not financial advice.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Inotiv Inc

Exchange NASDAQ
Headquaters West Lafayette, IN, United States
IPO Launch date 1997-11-25
President, CEO & Director Mr. Robert W. Leasure Jr.
Sector Healthcare
Industry Diagnostics & Research
Full time employees 1977
Full time employees 1977

Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. It operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DMS segment manufactures scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.